Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/D85F110C.svg?ark=w1%2F20260526%2FD85F110C)](https://nobleid.org/work/w1/20260526/D85F110C)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors